{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:19:12Z","timestamp":1775920752736,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.critrevonc.2025.104679","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T17:02:57Z","timestamp":1741021377000},"page":"104679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Molecular oncology of iodine refractory thyroid cancer current therapies and perspective"],"prefix":"10.1016","volume":"209","author":[{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104679_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-11-0129","article-title":"Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population","volume":"165","author":"Ahmed","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib5","doi-asserted-by":"crossref","unstructured":"Bazhenova, L., Liu, S.V., Lin, J.J., Lu, S., Drilon, A., Chawla, Fakih, Krzakowski, Paz-Ares, Blakely, Buchschacher Jr, Cassier, Fan, Folprecht, Mc.Callum, Pitcher, Chen, Freund, Springfeld, 2021. Efficacy and safety of entrectinib in patients with locally advanced\/metastatic NTRK fusion-positive (NTRK-fp) solid tumours | [WWW Document]. esmo.org. URL Poster 533P ESMO congress 2021 (accessed 2.20.23).","DOI":"10.1016\/j.annonc.2021.08.1055"},{"key":"10.1016\/j.critrevonc.2025.104679_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejso.2018.10.060","article-title":"PD-1\/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population","volume":"45","author":"Bi","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: american thyroid association anaplastic thyroid cancer guidelines task force","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104679_bib10","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib11","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2022.0115","article-title":"Dabrafenib versus dabrafenib +\u2009trametinib in BRAF -mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104679_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/ERC-11-0351","article-title":"Sorafenib in metastatic thyroid cancer","volume":"19","author":"Capdevila","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib14","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 Blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fsurg.2020.00043","article-title":"The changing face of in vitro culture models for thyroid cancer research: a systematic literature review","volume":"7","author":"Chew","year":"2020","journal-title":"Front. Surg."},{"key":"10.1016\/j.critrevonc.2025.104679_bib16","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41379-020-0574-4","article-title":"Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)","volume":"33","author":"Chu","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/thy.2015.0334","article-title":"Sorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis","volume":"26","author":"de Castroneves","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100041","article-title":"Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA","volume":"6","author":"Della Corte","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104679_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.667784","article-title":"Immune checkpoint inhibitors: new weapons against medullary thyroid cancer?","volume":"12","author":"Di Molfetta","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib21","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1186\/s12885-023-11362-8","article-title":"The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer","volume":"23","author":"Divoux","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000509457","article-title":"Benefits and limitations of TKIs in patients with medullary thyroid cancer: a systematic review and meta-analysis","volume":"10","author":"Efstathiadou","year":"2021","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2025.104679_bib25","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib26","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0061","article-title":"Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers","volume":"11","author":"Eszlinger","year":"2022","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2025.104679_bib27","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ijms24032398","article-title":"Antineoplastic activity of pazopanib in anaplastic thyroid cancer in primary culture","volume":"24","author":"Ferrari","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104679_bib28","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/14656566.2024.2393281","article-title":"Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer","volume":"25","author":"Ferrari","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.critrevonc.2025.104679_bib29","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.3390\/ijms25126734","article-title":"Antineoplastic effect of ALK inhibitor crizotinib in primary human anaplastic thyroid cancer cells with STRN\u2013ALK fusion in vitro","volume":"25","author":"Ferrari","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104679_bib30","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2025.104679_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12885-025-13590-6","article-title":"The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors","volume":"25","author":"Gall","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12022-020-09630-5","article-title":"Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma","volume":"31","author":"Girolami","year":"2020","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib35","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET -mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2019.00106","article-title":"Everolimus in anaplastic thyroid cancer: a case series","volume":"9","author":"Harris","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.748941","article-title":"Targeted therapy of papillary thyroid cancer: a comprehensive genomic analysis","volume":"12","author":"Hescheler","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib39","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1089\/thy.2019.0041","article-title":"A novel ALK fusion in pediatric medullary thyroid carcinoma","volume":"29","author":"Hillier","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13046-024-03009-8","article-title":"Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104679_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current guidelines for management of medullary thyroid carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104679_bib43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.surg.2011.09.022","article-title":"Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas","volume":"150","author":"Kouvaraki","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2025.104679_bib44","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post Hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib45","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2025.104679_bib46","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1200\/JCO.2021.39.15_suppl.6082","article-title":"Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: results of the AcS\u00e9 pembrolizumab study from unicancer","volume":"39","author":"Leboulleux","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/thy.2019.0202","article-title":"Remarkable response to ceritinib and brigatinib in an anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma previously treated with crizotinib","volume":"30","author":"Leroy","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib48","article-title":"Design of new drugs for medullary thyroid carcinoma","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib49","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12020-014-0380-1","article-title":"PI3K\/Akt\/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy","volume":"48","author":"Manfredi","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2025.104679_bib51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib52","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2020.09.004","article-title":"Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas","volume":"106","author":"Nozaki","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/ERC-19-0325","article-title":"Characterization of thyroid cancer driven by known and novel ALK fusions","volume":"26","author":"Panebianco","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00442","article-title":"Real-world experience of NTRK fusion\u2013positive thyroid cancer","author":"Park","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib56","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/cancers13081932","article-title":"NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis","volume":"13","author":"Pekova","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104679_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib58","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104679_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","article-title":"Update on fundamental mechanisms of thyroid cancer","volume":"11","author":"Prete","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7641940","article-title":"A BRAF V600E mutation in RET-negative medullary thyroid cancer","volume":"2020","author":"Robbins","year":"2020","journal-title":"Case Rep. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib61","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib63","first-page":"698","article-title":"Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial","volume":"102","author":"Schneider","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104679_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/348124","article-title":"Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial","volume":"2015","author":"Schneider","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib65","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET -altered tumors including RET -fusion+\u2009NSCLC and RET -mutant MTC: phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib66","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/thy.2019.0079","article-title":"Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence\/persistent disease in medullary thyroid carcinoma","volume":"29","author":"Shi","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib67","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jfma.2022.01.003","article-title":"Immunotherapy in anaplastic thyroid cancer: Case series","volume":"121","author":"Shih","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2025.104679_bib68","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2025.104679_bib69","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cncy.22519","article-title":"The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): update on the 2021 ATA ATC guidelines","volume":"130","author":"Silver Karcioglu","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/07435800.2024.2303632","article-title":"Advances in thyroid organoids research and applications","volume":"49","author":"Song","year":"2024","journal-title":"Endocr. Res."},{"key":"10.1016\/j.critrevonc.2025.104679_bib71","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.2147\/OTT.S278349","article-title":"Lenvatinib promotes the antitumor effect of doxorubicin in anaplastic thyroid cancer","volume":"13","author":"Su","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.critrevonc.2025.104679_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib75","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1200\/JCO.2016.34.15_suppl.6015","article-title":"Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma","volume":"34","author":"Sun","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib76","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2025.104679_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib78","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1158\/1078-0432.CCR-11-2700","article-title":"Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases","volume":"18","author":"Tamburrino","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104679_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/cancers14030579","article-title":"TROP-2, Nectin-4, GPNMB, and B7-H3 are potentially therapeutic targets for anaplastic thyroid carcinoma","volume":"14","author":"Toda","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104679_bib80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104679_bib82","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET -altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104679_bib83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104679_bib84","article-title":"ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma","volume":"26","author":"Zhang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2025.104679_bib85","article-title":"Modeling clinical radioiodine uptake by using organoids derived from differentiated thyroid cancer","volume":"166","author":"Zhang","year":"2025","journal-title":"Endocrinology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:25:26Z","timestamp":1744784726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":85,"alternative-id":["S1040842825000678"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104679","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular oncology of iodine refractory thyroid cancer current therapies and perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104679"}}